{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:05:16Z","timestamp":1794049516234,"version":"4.8.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.annonc.2024.09.005","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T08:17:08Z","timestamp":1726474628000},"page":"76-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"D.E.","family":"Rathkopf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6327-0176","authenticated-orcid":false,"given":"N.","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1720-5654","authenticated-orcid":false,"given":"J.E.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-738X","authenticated-orcid":false,"given":"V.","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.D.","family":"Runcie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Emamekhoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-8796","authenticated-orcid":false,"given":"Z.R.","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-5229","authenticated-orcid":false,"given":"R.","family":"Kandimalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Suryawanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.K.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pourdehnad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annonc.2024.09.005_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2024.09.005_bib3","unstructured":"European Cancer Information System. \u00a9European Union, 2021. Prostate cancer factsheet. Available at. https:\/\/visitors-centre.jrc.ec.europa.eu\/sites\/default\/files\/poster_flyer\/prostate_cancer_factsheet%5B1%5D_0.pdf. Accessed September 30, 2024."},{"issue":"10437","key":"10.1016\/j.annonc.2024.09.005_bib4","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.annonc.2024.09.005_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.005_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.annonc.2024.09.005_bib7","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMc1410239","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.annonc.2024.09.005_bib8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.005_bib9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.annonc.2024.09.005_bib10","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2024.09.005_bib11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2024.09.005_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.005_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.annonc.2024.09.005_bib14","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5928","key":"10.1016\/j.annonc.2024.09.005_bib15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.annonc.2024.09.005_bib16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.20517\/cdr.2022.15","article-title":"Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo","volume":"5","author":"Yehya","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"15","key":"10.1016\/j.annonc.2024.09.005_bib17","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.annonc.2024.09.005_bib18","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.annonc.2024.09.005_bib19","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2024.09.005_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2024.09.005_bib21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.annonc.2024.09.005_bib22","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"32","key":"10.1016\/j.annonc.2024.09.005_bib23","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10398","key":"10.1016\/j.annonc.2024.09.005_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.annonc.2024.09.005_bib25","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.09.005_bib26","unstructured":"National Cancer Institute. Prostate. Recent Trends in SEER Relative Survival Rates, 2004-2021. Available at https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=66&data_type=4&graph_type=2&compareBy=relative_survival_interval&chk_relative_survival_interval_1=1&chk_relative_survival_interval_3=3&chk_relative_survival_interval_5=5&chk_relative_survival_interval_10=10&hdn_sex=2&race=1&age_range=1&stage=106&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=1. Accessed July 4, 2024."},{"issue":"9","key":"10.1016\/j.annonc.2024.09.005_bib28","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1093\/oncolo\/oyad046","article-title":"Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer: results from an international study","volume":"28","author":"Barata","year":"2023","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.005_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"10.1016\/j.annonc.2024.09.005_bib30","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.09.005_bib31","article-title":"Prevalence and spectrum of AR ligand-binding domain mutations detected in circulating-tumor DNA across disease states in men with metastatic castration-resistant prostate cancer","volume":"8","author":"Antonarakis","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2024.09.005_bib32","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.005_bib33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","article-title":"Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing","volume":"174","author":"Viswanathan","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.annonc.2024.09.005_bib34","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.celrep.2014.11.008","article-title":"Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity","volume":"9","author":"Cai","year":"2014","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.005_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.eururo.2017.01.011","article-title":"Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns","volume":"72","author":"De Laere","year":"2017","journal-title":"Eur Urol"},{"issue":"13","key":"10.1016\/j.annonc.2024.09.005_bib36","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2024.09.005_bib37","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.005_bib38","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/s41598-021-81164-0","article-title":"Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells","volume":"11","author":"Rana","year":"2021","journal-title":"Sci Rep"},{"issue":"39","key":"10.1016\/j.annonc.2024.09.005_bib39","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Watson","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 7","key":"10.1016\/j.annonc.2024.09.005_bib40","doi-asserted-by":"crossref","first-page":"ND02","DOI":"10.1158\/1538-7445.AM2024-ND02","article-title":"Discovery of BMS-986365, a ligand-directed androgen receptor degrader (AR LDD) with a dual mechanism-of-action and best-in-class potential, for the treatment of advanced prostate cancer","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.annonc.2024.09.005_bib41","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00109-012-0885-0","article-title":"Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer","volume":"90","author":"Ren","year":"2012","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.annonc.2024.09.005_bib42","unstructured":"Predicine. BioPharma Solutions: PredicineCARE\u2122. Available at. https:\/\/www.predicine.com\/solutions-overview\/care\/. Accessed September 30, 2024."},{"issue":"suppl 8","key":"10.1016\/j.annonc.2024.09.005_bib43","first-page":"4244s","article-title":"Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors","volume":"46","author":"McCarty","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2024.09.005_bib44","unstructured":"Food and Drug Administration. Oncology Center of Excellence: Project Optimus. Available at. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus. Accessed September 30, 2024."},{"key":"10.1016\/j.annonc.2024.09.005_bib45","doi-asserted-by":"crossref","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","article-title":"LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)","volume":"34","author":"Sartor","year":"2023","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2024.09.005_bib46","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2024.09.005_bib47","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.annonc.2024.09.005_bib48","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.005_bib49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","article-title":"A\u00a0somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer","volume":"174","author":"Takeda","year":"2018","journal-title":"Cell"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.09.005_bib50","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1200\/JCO.2024.42.16_suppl.5011","article-title":"ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1\/2 study","volume":"42","author":"Petrylak","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.annonc.2024.09.005_bib51","article-title":"Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Gao","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.005_bib52","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300171","article-title":"Targeted inhibition of CYP11A1 in castration-resistant prostate cancer","volume":"3","author":"Fizazi","year":"2024","journal-title":"NEJM Evid"}],"updated-by":[{"DOI":"10.1016\/j.annonc.2026.01.016","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000}}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424040018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424040018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T02:19:31Z","timestamp":1741918771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424040018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0923753424040018"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.09.005","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}